Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN). The MISSION Phase 2 trial is an open-label study with...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...
Pandion Therapeutics, Inc. (NASDAQ: PAND), a clinical-stage biotechnology company developing modular biologics for autoimmune regulation, has entered into a definitive agreement with Merck (NYSE: MRK) to be acquired for $60 per share in cash, for an approximate total equity value of $1.85 billion. The acquisition...
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is developing innovative approaches that help modulate the immune system to combat, ocular, fibrosis and Cytokine release syndrome. The Company recently released topline results from a Phase III trial of Reproxalap being developed for the treatment of dry eye syndrome....
Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...
Cyclerion Therapeutics (NASDAQ: CYCN), a clinical-stage Company, announced the failure of its drug candidate praliciguat in meeting the primary endpoints in two separate clinical studies, in diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF). Praliciguat is a soluble guanylate cyclase (sGC) stimulator...
Medicinova (NASDAQ: MNOV), a Company developing small molecule therapeutics, has received notice of allowances for grant of new patents for MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS) from the Canadian Intellectual Property Office, in addition to receiving a Notice of Allowance for...
Adverum Biotechnologies (NASDAQ: ADVM), a clinical-stage Company focused on developing therapeutics for ocular and rare diseases through gene therapy, released additional clinical data from its ongoing OPTIC phase 1 clinical trial of ADVM-022. ADVM-022, the Company’s lead ocular candidate, is an adeno- associated virus (AAV)....
Nonalcoholic Steatohepatitis (NASH) is a form of Non-Alcoholic Fatty Liver Disease (NAFLD) and is characterized by the buildup of FAT in the liver. This condition is marked by hepatitis, inflammation, cell damage and fat deposits in the liver. These fat deposits can cause fibrosis of...
CytoDyn Inc (OTCQB: CYDY), a clinical stage biotechnology company, announced the filing of an Investigational Drug License (IND) for treatment of NASH with Leronlimab. The drug candidate is a humanized IgG4 mAb CCR5 antagonist that has been granted the Fast Track designation by the FDA...
